Ito T, Young MJ, Li R, et al. Paralog knockout profiling identifies DUSP4 and DUSP6 as a digenic dependence in MAPK pathway-driven cancers. Nat Genet. 2021;53(12):1664-1672. doi:10.1038/s41588-021-00967-z.
Viswanathan VS, Ryan MJ, Dhruv HD, et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature. 2017;547(7664):453-457. doi:10.1038/nature23007.
Joung J, Engreitz JM, Konermann S, et al. Genome-scale activation screen identifies a lncRNA locus regulating a gene neighbourhood. Nature. 2017;548(7667):343-346. doi:10.1038/nature23451.
Hazar-Rethinam M, Kleyman M, Han C, et al. Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in Colorectal Cancer. Cancer Discov. 2018;8(4):417-427. doi:10.1158/2159-8290.CD-17-1227.
Izar B, Sharfman W, Hodi S, et al. A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status. Cancer Med. 2017;6(8):1904-1914. doi:10.1002/cam4.1140.
Chan AT, Moayyedi P. Signature Celebration of Gastroenterology, Colorectal Cancer. Gastroenterology. 2018;154(4):767-770. doi:10.1053/j.gastro.2017.11.029.
Shao W, Mishina YM, Feng Y, et al. Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF. Cancer Res. 2018;78(6):1537-1548. doi:10.1158/0008-5472.CAN-17-2033.
Grant AR, Hemphill SE, Vincent LM, Rehm HL. Reclassification of the p.Ile208Val variant by case-level data sharing. Cold Spring Harb Mol Case Stud. 2018;4(5). doi:10.1101/mcs.a002675.
Sidhom E-H, Kim C, Kost-Alimova M, et al. Targeting a Braf/Mapk pathway rescues podocyte lipid peroxidation in CoQ-deficiency kidney disease. J Clin Invest. 2021;131(5). doi:10.1172/JCI141380.
Stover DG, Wagle N. Precision medicine in breast cancer: genes, genomes, and the future of genomically driven treatments. Curr Oncol Rep. 2015;17(4):15. doi:10.1007/s11912-015-0438-0.